Therapeutic Advances and Emerging Treatments in Inflammatory Bowel Disease
A Special Issue of Journal of Clinical Medicine (ISSN 2077-0383) belonging to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: closed (20 August 2026) | Viewed by 305
Editor
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to our upcoming article series entitled “Therapeutic Advances and Emerging Treatments in Inflammatory Bowel Disease.” This collection aims to provide a comprehensive and up-to-date overview of the rapidly evolving therapeutic landscape in IBD, highlighting both established strategies and cutting-edge innovations. We seek high-quality manuscripts that explore topics such as novel biologics and small molecules, optimization of current therapies, precision medicine approaches, biomarkers for treatment selection, endoscopic and histologic targets, and emerging modalities, encompassing antifibrotic agents and microbiome-directed approaches. Original research, systematic or narrative reviews, clinical perspectives, and real-world evidence studies are all welcome. Our goal is to offer clinicians and researchers a reference that advances understanding and supports evidence-based decision-making in the management of ulcerative colitis and Crohn’s disease. We would be delighted to count on your expertise and scientific contribution to enrich this focused series. Please let us know if you are interested in participating.
Dr. Laura Ramos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease
- therapeutic advances emerging treatments
- biologics and small molecules
- precision medicine in IBD
- pharmacokinetic model
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
